26.03.2020 - 08:03 Uhr

Newly published data in Cancer Immunology, Immunotherapy support the potential of Secarna Pharmaceuticals' LNA-modified ASOs to effectively block important immunosuppressive pathway

Secarna Pharmaceuticals GmbH & Co. KG,

Tel.: +49 (0)211.52 92 52 22

26.03.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

1006613  26.03.2020